First patient included in new clinical investigation on pressure ulcers

RLS Global's new clinical investigation with ChloraSolv for the treatment of pressure ulcers includes six clinics in Sweden, Finland and the UK. The first patient was enrolled on September 1 at a clinic in the UK.
The investigation has been approved by authorities in all three countries.

Pressure ulcers belong to the group of hard-to-heal wounds and cause much suffering and high costs worldwide. Studies show that pressure ulcers affect as many as over 10 (6-27) percent of all hospitalised patients in Europe (ref). Previous investigations have shown that ChloraSolv is effective and safe in the treatment of hard-to-heal leg ulcers and diabetic foot ulcers in need of debridement. This investigation is being carried out to extend the use of ChloraSolv and thus the opportunity to help even more patients. 

Ref: Journal of Wound Care. 2019 Nov 2;28(11):710-719

 

THIS IS CHLORASOLV
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.¹ ChloraSolv does not damage healthy tissue and is well tolerated by the patient.

1. Eliasson, B., Fagerdahl, A.M., Jönsson, A., Apelqvist, J. Debriding effect of amino acid-buffered hypochlorite on hard-to-heal wounds covered by devitalized tissue: pilot study. Journal of Wound Care (June 2021) 30(6):455-464.

 

 

 

 

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17^th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

FOR MORE INFORMATION, PLEASE CONTACT:
Roland Frösing, acting CEO, RLS Global
E-mail: [e-mail]
Phone: [phone]

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global

https://news.cision.com/rls-global-ab/r/first-patient-included-in-new-clinical-investigation-on-pressure-ulcers,c3830134

(c) 2023 Cision. All rights reserved., source Press Releases - English